Pages that link to "Q37768299"
Jump to navigation
Jump to search
The following pages link to ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association (Q37768299):
Displaying 50 items.
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Q22241919) (← links)
- 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Q22241922) (← links)
- Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants (Q24273409) (← links)
- Pharmacogenomics and cardiovascular disease (Q26997380) (← links)
- Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation (Q27011524) (← links)
- What Could be Changed in the 2012 Taiwan ST-Segment Elevation Myocardial Infarction Guideline? (Q28468713) (← links)
- Genetics and cardiovascular disease: a policy statement from the American Heart Association. (Q30418104) (← links)
- Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1 (Q30840104) (← links)
- Applied pharmacogenomics in cardiovascular medicine (Q33846255) (← links)
- Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers (Q33963651) (← links)
- Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. (Q34161006) (← links)
- Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis (Q34624862) (← links)
- Pharmacogenomics: the genetics of variable drug responses (Q34976915) (← links)
- Tailored antiplatelet therapy and clinical adverse outcomes (Q35032042) (← links)
- Antiplatelets in secondary stroke prevention (Q35091647) (← links)
- Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness (Q35846595) (← links)
- Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others (Q35955515) (← links)
- Evolving Research and Stakeholder Perspectives on Pharmacogenomics (Q36573872) (← links)
- Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice (Q36702588) (← links)
- Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor (Q36807413) (← links)
- Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy (Q36995923) (← links)
- CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful? (Q37387416) (← links)
- Diffuse Alveolar Hemorrhage in Patients Undergoing Neurointervention: A Case Report (Q37401274) (← links)
- Should platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes? (Q37588812) (← links)
- Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives (Q37724614) (← links)
- Coronary stents: factors contributing to perioperative major adverse cardiovascular events (Q37819557) (← links)
- Genetic Influences on Neural Plasticity (Q37822563) (← links)
- Functional Testing Methods for the Antiplatelet Effect of P2Y 12 Receptor Antagonists (Q37841568) (← links)
- Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation). (Q37876347) (← links)
- Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose? (Q37907902) (← links)
- The pharmacogenetics of antiplatelet agents: towards personalized therapy? (Q37913976) (← links)
- Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance (Q37914050) (← links)
- Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy (Q37955342) (← links)
- Antiplatelet therapy in acute coronary syndromes. (Q37965609) (← links)
- Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients (Q37982427) (← links)
- Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus (Q38007860) (← links)
- What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice (Q38052474) (← links)
- Overcoming aspirin treatment failure in diabetes. (Q38055245) (← links)
- Controversies in the use & implementation of drug-eluting stent technology. (Q38079934) (← links)
- Pharmacogenomics of oral antiplatelet drugs. (Q38195628) (← links)
- Genetic determinations of variable responsiveness to clopidogrel and implications for neurointerventional procedures (Q38246009) (← links)
- Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. (Q38347110) (← links)
- Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention (Q38682772) (← links)
- Genomic translational research: Paving the way to individualized cardiac functional analyses and personalized cardiology (Q38774369) (← links)
- The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway (Q38838327) (← links)
- Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy (Q38971852) (← links)
- Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy (Q38998163) (← links)
- Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature (Q39037199) (← links)
- Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation (Q39540305) (← links)
- Stent thrombosis: incidence, predictors and new technologies (Q41962888) (← links)